Magnetar Financial LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 88.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,000 shares of the medical research company's stock after selling 23,958 shares during the period. Magnetar Financial LLC's holdings in IQVIA were worth $590,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Synergy Asset Management LLC bought a new position in shares of IQVIA during the fourth quarter valued at $33,000. Avior Wealth Management LLC boosted its holdings in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after acquiring an additional 93 shares during the period. SBI Securities Co. Ltd. purchased a new stake in IQVIA in the fourth quarter worth approximately $60,000. Finally, UMB Bank n.a. grew its position in IQVIA by 72.8% in the 4th quarter. UMB Bank n.a. now owns 401 shares of the medical research company's stock worth $79,000 after purchasing an additional 169 shares during the period. 89.62% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on IQV shares. Stifel Nicolaus dropped their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating on the stock in a research note on Friday, February 7th. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. BTIG Research lowered shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Finally, Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research report on Monday, February 3rd. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $249.05.
View Our Latest Report on IQV
IQVIA Price Performance
Shares of IQVIA stock traded down $5.04 on Tuesday, hitting $181.07. 1,566,007 shares of the company traded hands, compared to its average volume of 1,242,649. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The business has a 50-day simple moving average of $194.24 and a 200 day simple moving average of $207.29. IQVIA Holdings Inc. has a 52 week low of $179.28 and a 52 week high of $253.84. The stock has a market capitalization of $31.93 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
